What are Antineoplastic drugs?

Antineoplastic drugs are pharmacologic agents that share a common mechanism (typically targeting VEGF-A). 0 are currently marketed, with 4 more in clinical development.

Antineoplastic

0 marketed 2 in Phase 3 2 in Phase 2

This page covers all Antineoplastic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF-A, Thymidylate synthase, Thymidylate synthase, DNA.

Targets

VEGF-A · Thymidylate synthase · Thymidylate synthase, DNA

Phase 3 pipeline (2)

Trifluridine/tipiracil + bevacizumab · Second Affiliated Hospital, School of Medicine, Zhejiang University · Oncology
Trifluridine/tipiracil is a thymidine kinase 1 inhibitor and tipiracil is a thymidine phosphorylase inhibitor, which work together to inhibit DNA synthesis in cancer cells. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis.
UFT, Calcium Folinate, PSK · Iwate Medical University · Oncology
UFT is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor.

Phase 2 pipeline (2)

Fluorouracil Implants · Jiangsu Simcere Pharmaceutical Co., Ltd. · Oncology
Fluorouracil implants work by releasing fluorouracil, a thymidylate synthase inhibitor, which interferes with DNA synthesis and function.
Capecitabine, Cyclophosphamide · Vastra Gotaland Region · Oncology
Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Cyclophosphamide is an alkylating agent that attaches an alkyl group to the DNA of cancer cells, thereby interfering with their replication.